https://www.selleckchem.com/pr....oducts/liraglutide.h
6%, 17.6%, and 54.7% of patients, respectively. In multivariate Cox regression, detectable miR-BART7-3p and EBV-DNA were independent risks for shorter DMFS (HR=4.13, 95%CI 1.89-9.01, p less then 0.001; HR = 2.14, 95%CI 1.04-4.42, p=0.039). Four-years DMFS rate was 92.0% in subjects (n=156) with neither detectable miR-BART7-3p nor EBV DNA, 80.0% in subjects (n=65) with either detectable miR-BART7-3p or EBV-DNA, and 52.9% in subjects (n=24) with both detectable miR-BART7-3p and EBV-DNA after radiotherapy (p less then 0.001). Circulati
Like
Comment
Share
